Acasti Announces Alignment With FDA On GTX-104 Pivotal Phase 3 Safety Trial Protocol And Confirms Planned Initiation Of STRIVE-ON In aSAH Patients In Calendar Q4 2023
Portfolio Pulse from Benzinga Newsdesk
Acasti Pharma has announced its alignment with the FDA on the GTX-104 Pivotal Phase 3 Safety Trial Protocol and confirmed the planned initiation of STRIVE-ON in aSAH patients in Q4 2023.
July 05, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acasti Pharma's alignment with the FDA on the GTX-104 Phase 3 Safety Trial Protocol and the planned initiation of STRIVE-ON in aSAH patients in Q4 2023 could potentially boost investor confidence.
The alignment with the FDA on the pivotal Phase 3 trial protocol for GTX-104 indicates regulatory progress, which is a positive signal for investors. The planned initiation of STRIVE-ON in aSAH patients in Q4 2023 also shows the company's commitment to advancing its pipeline, which could further boost investor confidence.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100